Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Hepatitis C treatment

How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

Editor's pick
The Motley Fool
15 January 2015
Hepatitis C treatment

India rejects Gilead's Hepatitis C drug patent request

Editor's pick
Reuters
14 January 2015
Hepatitis C treatment

US: Prime Therapeutics breaks from competition, strikes deals to prefer both Harvoni, Viekira hepatitis C drugs

Editor's pick
Prime Therapeutics press release
13 January 2015
New & experimental hepatitis C treatment

Merck speeds up drug-submission plans for hep C, lung cancer

Editor's pick
Reuters
13 January 2015
Finance & funding

South Africa secures 'world's lowest prices' for HIV drugs

Editor's pick
Business Day
7 January 2015
Pharmaceutical industry

Gilead, Janssen Expand HIV Combo Collaborations

Editor's pick
Genetic Engineering & Biotechnology News
30 December 2014
Pharmaceutical industry

Gilead Sciences, Inc. Can't Do It Alone

Editor's pick
Motley Fool
30 December 2014
Health services & systems

US: Consumer Group Sues Aetna, Claiming Discrimination Against HIV Patients

Editor's pick
New York Times
26 December 2014
Hepatitis C treatment

Even with New AbbVie Drug, Many Hepatitis C Patients Are Being Turned Away from Treatment

Editor's pick
Hepatitis C News
23 December 2014
Hepatitis C treatment

Gilead slides after hepatitis drug setback

Editor's pick
Financial Times (free registration required)
23 December 2014
Drug-resistant TB

Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound

Editor's pick
PR Newswire
12 December 2014
Pharmaceutical industry

Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Editor's pick
Chimicles & Tikellis press release
12 December 2014
Hepatitis C treatment

Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Editor's pick
Hepatitis C New Drugs
10 December 2014
New & experimental HIV treatments

European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Editor's pick
Janssen
25 November 2014
Access to healthcare

Zimbabwe: Stealing Lives

Editor's pick
Al Jazeera (video)
24 November 2014
New & experimental hepatitis C treatment

CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Editor's pick
AbbVie press release
21 November 2014
Pharmaceutical industry

Pharmaceutical Industry Doing More to Improve Access to Medicine in Developing Countries; Performance on Some Aspects Lags

Editor's pick
Access to Medicine Index
18 November 2014
New & experimental HIV treatments

HIV Drug Development Pipeline Update, Fall 2014 Edition

Editor's pick
The Body Pro
17 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014
Pharmaceutical industry

HIV generics in the U.S.: Sooner or later?

Editor's pick
The Body
10 November 2014
New & experimental HIV treatments

Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

Editor's pick
BioPharma Dive
7 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Generic medicines

Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

News
4 November 2014
HIV treatment

How Will Generic Drugs Affect HIV Treatment in the U.S.?

Editor's pick
The Body
31 October 2014